4
Changes in Ownership
VERTEX PHARMACEUTICALS INC / MA Filed Acc 0001209191-23-020244
EVP & Chief Financial Officer sold 2,000 shares at an average $296.39 ($592,786)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
WAGNER CHARLES F JR · EVP & Chief Financial Officer
Table I: Non-derivative
6 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2023-03-17 | Sale : show line 1 in the form 10b5-1 | −360 | $294.52 | $106,027 | 53,019 | D |
| 2023-03-17 | Sale : show line 2 in the form 10b5-1 | −784 | $295.43 | $231,617 | 52,235 | D |
| 2023-03-17 | Sale : show line 3 in the form 10b5-1 | −240 | $296.30 | $71,112 | 51,995 | D |
| 2023-03-17 | Sale : show line 4 in the form 10b5-1 | −360 | $298.09 | $107,312 | 51,635 | D |
| 2023-03-17 | Sale : show line 5 in the form 10b5-1 | −240 | $299.58 | $71,899 | 51,395 | D |
| 2023-03-17 | Sale : show line 6 in the form 10b5-1 | −16 | $301.13 | $4,818 | 51,379 | D |
| Open-market sales · 2,000 sh · avg $296.39 · $592,786 | ||||||
Loading xslF345X04/doc4.xml…